Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02977507 · ClinicalTrials.gov registry record · NA
Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma
A NA study of Melasma, sponsored by Allergan.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT02977507: Completed NA study of Melasma, sponsored by Allergan.
NCT02977507 is a NA study of Melasma that has completed, run by Allergan. The registered enrollment target is 18 participants, below the 43-participant average among 8 other Melasma trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02977507, a NA study of Melasma, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the efficacy and tolerability of Lytera 2.0 versus 4% hydroquinone in the improvement of the appearance of moderate facial melasma.
Primary Outcome
The investigator assessed the participant's facial skin for the severity of symmetrical facial melasma on the left and the right side of the face using the Melasma Severity Rating Scale. The score ranges from 0 to 3, where 0=Cleared: color of melasma lesions approximately equivalent to surrounding normal skin or with minimal residual hyperpigmentation, 1=Mild: color slightly darker than the surrounding normal skin, 2=Moderate: color moderately darker than the surrounding normal skin and 3=Severe
Conditions Studied
Interventions
- OTHER Lytera 2.0
- DRUG 4% Hydroquinone Topical Cream
- OTHER SkinMedica Facial Cleanser
- OTHER SkinMedica Rejuvenative Moisturizer
- OTHER SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen
Study Locations (1)
New York
- Mount Sinai St. Luke's Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-12-13 |
| Est. Completion | 2017-10-09 |
| Phase | NA |
What the finished NCT02977507 record still lists
NCT02977507 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 43-participant average among 8 other Melasma trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Melasma appearing as the primary indexed condition, and to 5 interventions - of which Lytera 2.0 is the first listed.
NCT02977507 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02977507 about?
NCT02977507 is a clinical study titled "Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma". The objective of this study is to evaluate the efficacy and tolerability of Lytera 2.0 versus 4% hydroquinone in the improvement of the appearance of moderate facial melasma.
What is the current status of trial NCT02977507?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2016-12-13. Estimated completion is 2017-10-09.
What conditions does trial NCT02977507 study?
This clinical trial studies the following conditions: Melasma.
What interventions are being tested in trial NCT02977507?
The interventions under investigation include: Lytera 2.0 (OTHER), 4% Hydroquinone Topical Cream (DRUG), SkinMedica Facial Cleanser (OTHER), SkinMedica Rejuvenative Moisturizer (OTHER), SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen (OTHER).
Who is sponsoring clinical trial NCT02977507?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02977507 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melasma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02977507's enrollment target sits among peer trials
18 7th of 8 higher than 2 of 8 other Melasma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melasma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
-
LaseMD System for the Treatment of Melasma
ACTIVE NOT RECRUITING · NA
-
Efficacy and Safety of PiQo4 Device for Treatment of Melasma
COMPLETED · NA
-
A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma
COMPLETED · NA
-
Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI